Diabetes Drug Avandia Could Weaken Bones
Get a Free legal review of your
case
Study suggests it boosts production of bone-eroding
cells
December 2, 2007--An article in HealthDay News, reports
that Avandia, a type 2 diabetes medication used by millions, may contribute to
bone loss, according to a new study conducted in mice.
Health
professionals worry that, over the long term, Avandia (rosiglitazone) may speed
osteoporosis, the thinning of the bones that can lead to dangerous and even
fatal fractures.
Study senior author Ron Evans, a professor at the Salk
Institute for Biological Studies in La Jolla, Calif, was quoted in the article
as saying: "Our study suggests that long-term rosiglitazone usage in the
treatment of type II diabetes may cause osteoporosis due to both increased bone
resorption and decreased bone formation."
He added, "Because Avandia is
effective in controlling glucose and restoring the body's sensitivity to
insulin, we do not recommend that people stop their treatment. You must balance
the benefits against the complications."
If you or a loved one has
suffered cardiac complications after ingesting Avandia, you deserve the guidance
of a knowledgeable drug attorney. Get a free case review by filling out the form
below.
see also:
Second Black Box?
FDA: Black Box Warning Label Decision Pending on Avandia Diabetes DrugFDA to Announce Decision on Black Box for Avandia Soon--Lawsuit Info
FDA Safety Information
FDA Releases New Safety Info on Diabetes Drug Avandia and Side EffectsFDA Updates Public on Safety Information for Avandia and Side Effects
News & Warnings
Avandia Breaking News: Glaxo Warned in 2001 about Misleading MarketingBloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001


